© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers
Trametinib Shows Promising Benefit for Low-Grade Serous Ovarian Cancer
May 21, 2020
Encouraging survival outcomes were seen with trametinib in patients with low-grade serous ovarian cancer treated in a phase II/III clinical trial.
Personalized Treatment Approaches Improve Outcomes for Patients With Ovarian Cancer
May 20, 2020
In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.
Immunotherapy Advances the Treatment Landscape of Endometrial Cancers
May 07, 2020
Shannon N. Westin, MD, MPH, FACOG, discusses the evolving role of immunotherapy as treatment of patients with endometrial cancer.
FDA Approves Niraparib As Frontline Maintenance in Advanced Ovarian Cancer
April 29, 2020
"This approval is an important step forward in the treatment of ovarian cancer. In my opinion, maintenance treatment with niraparib should be considered an option for appropriate patients who responded to first-line platinum-based chemotherapy versus active surveillance."
Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian Cancer
April 25, 2020
In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.
Targeted Agent Demonstrates Strong Activity in Uterine Serous Carcinoma
April 24, 2020
"Adavosertib demonstrated promising preliminary clinical activity in patients with unselected uterine serous cancer."
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial Toxicity
April 24, 2020
Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
Dostarlimab on the Road to Progress in dMMR Endometrial Cancer
April 24, 2020
“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Novel Monoclonal Antibody Demonstrates Clinical Activity in Gynecologic Malignancies
April 23, 2020
"We are seeing clinically meaningful monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response, a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable responses and disease control in paclitaxel-experienced patients."